LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) ...

Application of Ad vectors to select applications such as therapeutic angiogenesis has generated cautious optimism. An understanding of Ad vector-induced toxicity is continuing to grow and is leading ...